NZ707246A - Uses of Bremelanotide in Therapy for Female Sexual Dysfunction - Google Patents

Uses of Bremelanotide in Therapy for Female Sexual Dysfunction

Info

Publication number
NZ707246A
NZ707246A NZ707246A NZ70724613A NZ707246A NZ 707246 A NZ707246 A NZ 707246A NZ 707246 A NZ707246 A NZ 707246A NZ 70724613 A NZ70724613 A NZ 70724613A NZ 707246 A NZ707246 A NZ 707246A
Authority
NZ
New Zealand
Prior art keywords
bremelanotide
sexual dysfunction
female sexual
therapy
administration
Prior art date
Application number
NZ707246A
Other languages
English (en)
Inventor
Carl Spana
Robert Jordan
Jeffrey Edelson
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ707246(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of NZ707246A publication Critical patent/NZ707246A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
NZ707246A 2012-11-05 2013-11-05 Uses of Bremelanotide in Therapy for Female Sexual Dysfunction NZ707246A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (1)

Publication Number Publication Date
NZ707246A true NZ707246A (en) 2019-03-29

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ707246A NZ707246A (en) 2012-11-05 2013-11-05 Uses of Bremelanotide in Therapy for Female Sexual Dysfunction

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN117860866A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (1) GEP20196947B (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915A1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
WO2003006620A2 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60112440T2 (de) * 2000-05-31 2006-04-20 Novo Nordisk A/S Wegwerfbare zweispitzige injektionsnadel
MX2007006973A (es) * 2004-12-09 2007-08-15 West Pharm Serv Inc Acoplamiento para un dispositivo de auto-inyeccion.
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
CA2727317C (en) * 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
EP2501225B1 (en) * 2009-11-16 2017-11-01 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
AU2011242602B2 (en) * 2010-04-21 2015-06-18 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
UA118656C2 (uk) 2019-02-25
PH12015500915B1 (en) 2015-06-29
US20240335502A1 (en) 2024-10-10
US20180085425A1 (en) 2018-03-29
MX362610B (es) 2019-01-28
AU2013337341B2 (en) 2018-02-22
EP2916856B2 (en) 2023-10-18
SG11201502949QA (en) 2015-06-29
ES2701444T3 (es) 2019-02-22
EP2916856B1 (en) 2018-09-19
ES2701444T5 (es) 2024-05-21
US9700592B2 (en) 2017-07-11
FI2916856T4 (fi) 2024-01-15
DK2916856T4 (da) 2024-01-22
ZA201503128B (en) 2016-11-30
BR112015009936A8 (pt) 2019-09-17
GEP20196947B (en) 2019-02-11
IL238276B (en) 2020-04-30
AU2013337341A1 (en) 2015-05-07
JP6567971B2 (ja) 2019-08-28
US20190216888A1 (en) 2019-07-18
EA032959B1 (ru) 2019-08-30
US20140378392A1 (en) 2014-12-25
CA2890081A1 (en) 2014-05-08
WO2014071339A3 (en) 2014-06-12
US9352013B2 (en) 2016-05-31
EP2916856A4 (en) 2016-06-22
JP2016503406A (ja) 2016-02-04
MX2015005486A (es) 2015-11-13
KR20150081345A (ko) 2015-07-13
US20210060120A1 (en) 2021-03-04
IL238276A0 (en) 2015-06-30
US10286034B2 (en) 2019-05-14
PH12015500915A1 (en) 2015-06-29
KR102253526B1 (ko) 2021-05-18
EP2916856A2 (en) 2015-09-16
DK2916856T3 (en) 2019-01-14
EA032959B9 (ru) 2019-11-27
PL2916856T5 (pl) 2024-01-29
BR112015009936A2 (pt) 2017-07-11
CN104755094A (zh) 2015-07-01
EA201590760A1 (ru) 2015-10-30
CN117860866A (zh) 2024-04-12
PL2916856T3 (pl) 2019-02-28
WO2014071339A2 (en) 2014-05-08
US20150231196A1 (en) 2015-08-20
US20220362328A1 (en) 2022-11-17
HK1211227A1 (en) 2016-05-20
MY179755A (en) 2020-11-12

Similar Documents

Publication Publication Date Title
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
NZ732507A (en) Improved compositions for treating muscular dystrophy
GB2491775A (en) Pulsatile drug release
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
NZ625391A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EA201400767A1 (ru) Подкожное терапевтическое применение ингибитора dpp-4
NZ714963A (en) Compositions and methods for treating anemia
MX392388B (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
AU2017312811A8 (en) Liquid naloxone spray
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
NZ707246A (en) Uses of Bremelanotide in Therapy for Female Sexual Dysfunction
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
RU2012114097A (ru) Терапевтический агент против хронической боли
WO2012121529A3 (ko) Ｎｉｎｊｕｒｉｎ 활성 억제제를 포함하는 신경세포 또는 내피세포 재생용 조성물
RU2011111891A (ru) Способ профилактики системного амилоидоза и его нефропатической формы у экспериментальных животных
UA92302C2 (ru) Лекарственное средство для терапии злокачественных опухолей и способ лечения злокачественных опухолей с его использованием
NZ747111A (en) Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
UA104971C2 (uk) Спосіб імуномодуляції при імунодефіцитному стані організму тварин
UA77145U (ru) Способ лечения острого инфаркта миокарда с зубцом q и ранней систолической дисфункцией левого желудочка

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2020 BY CPA GLOBAL

Effective date: 20190919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2021 BY CPA GLOBAL

Effective date: 20200924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2022 BY CPA GLOBAL

Effective date: 20210924

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2023 BY CPA GLOBAL

Effective date: 20220923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2024 BY CPA GLOBAL

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2025 BY COMPUTER PACKAGES INC

Effective date: 20241030

ASS Change of ownership

Owner name: COSETTE PHARMACEUTICALS, INC., UY

Effective date: 20250814

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 NOV 2026 BY COMPUTER PACKAGES INC

Effective date: 20251017